Hoffman Robert E. — SEC Form 4 filings
SEC reporting owner CIK 1166288. 11 Form 4 filings on record with FilingPulse; latest filed 2026-07-13.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-08-27 to 2026-07-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. (ESPR) | Director | 4 | — | — | 7 |
| FibroBiologics, Inc. (FBLG) | Director | 3 | — | — | 3 |
| CytoDyn Inc. (CYDY) | Chief Financial Officer | 2 | — | — | 2 |
| TuHURA Biosciences, Inc./NV (HURA) | Director | 2 | — | — | 2 |
Form 4 filings — Hoffman Robert E.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-13 | 4 | Esperion Therapeutics, Inc. (ESPR) | Disposition to issuer (D): 85,153 · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 7,040 (derivative) | EDGAR |
| 2026-06-23 | 4 | FibroBiologics, Inc. (FBLG) | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 79,873 @ $0 | EDGAR |
| 2026-03-24 | 4 | CytoDyn Inc. (CYDY) | Grant/award (A): 4,874,691 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | TuHURA Biosciences, Inc./NV (HURA) | Grant/award (A): 156,240 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | FibroBiologics, Inc. (FBLG) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 5,280 @ $0 · Grant/award (A): 7,040 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | CytoDyn Inc. (CYDY) | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | TuHURA Biosciences, Inc./NV (HURA) | Grant/award (A): 51,275 (derivative) @ $0 | EDGAR |
| 2024-08-27 | 4 | FibroBiologics, Inc. (FBLG) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1166288 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →